
SKIN Stock Forecast & Price Target
SKIN Analyst Ratings
Bulls say
SkinHealth Systems is executing better in an increasingly competitive market, with revenue declining -8% y/y in 2Q26 but adjusted EBITDA exceeding guidance due to gross margin expansion and disciplined expense management. The company's strategic priorities, including the launch of a new rental program and expansion into adjacent categories, provide additional potential for growth. Key innovation catalysts include a new rental program, upcoming product launches, and continued traction in existing products. While there are risks of execution and competition, the company's strong cash position and ongoing development of its next-generation platform provide a solid foundation for future growth.
Bears say
SkinHealth Systems is facing ongoing challenges in its medical aesthetics business due to declines in equipment sales and softness in the EMEA region. This has resulted in reduced revenue and profitability, and the company's guidance for the remainder of the year is below expectations. There are also concerns over the company's ability to generate positive free cash flow and manage its longer-term debt obligations. In addition, SkinHealth Systems faces competitive pressures and regulatory risks that could further impact its revenue and brand reputation.
This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares